← Back to Search
Multicentric Study On Malignant Pleural Mesothelioma In Turkey: Clinicopathologic And Survival Characteristics Of 282 Patients
E. T. Elkıran, M. A. Kaplan, A. Sevinç, S. Aksoy, U. Demirci, M. Seker, H. Harputluoğlu, N. Ozdemir, F. Işik, A. Ulaş, M. Inanç, U. Arslan, G. Dogu, A. Isikdogan, S. Buyukberber, Anatolian Society of Medical Oncology Group
Published 2012 · Medicine
Download PDFAnalyze on Scholarcy
Malignant pleural mesothelioma (MPM) is a relatively rare, but aggressive tumor that causes high mortality. The major risk factor involved in the etiology is environmental and occupational exposure to asbestos. The optimal modality of therapy is controversial. The present study retrospectively evaluated the data pertinent to 282 patients who were examined and treated in 11 different medical oncology centers in Turkey. There were 161 males (57.1 %) and 121 females (42.9 %), with a mean age of 56.38 ± 12.07 years. Surgery was used in 74 patients, 21 patients (28.4 %) received only chemotherapy and 28 patients (37.8 %) received chemoradiotherapy after surgery. The median survival in patients who were administered adjuvant therapy after surgery was 24 months, while the median survival in patients who had only surgery was 6 months (p = 0.029). 106 patients were administered pemetrexed-platinum combination and 35 patients were administered gemcitabine-platinum combination as front-line chemotherapy. Median survival, 1- and 2-year survival rates in patients who received platinum analogues and pemetrexed or gemcitabine combinations were found statistically similar (p = 0.15). The median survival for all patients with MPM in our study was 18 months. The main factors influencing the overall survival were stage of the disease (p = 0.020), performance status (p < 0.001), asbestos exposure (p = 0.030) and mesothelioma histological subtypes (p < 0.001). Results of our study suggest that multi-modality treatment regimens consisting of surgery, radiotherapy and chemotherapy prolong overall survival. Survival rates in patients who received combining platinum analogues with pemetrexed or gemcitabine as front-line chemotherapy were found similar.
This paper references
A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
M. Lucchi (2007)
Pleural calcification associated with exposure to chrysotile asbestos in southeast Turkey.
S. Yazicioglu (1976)
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
V. Rusch (1996)
Systemic drug therapy of malignant pleural mesothelioma.
A. Ardizzoni (1998)
An epidemiological study in an Anatolian village environmentally exposed to tremolite asbestos.
Y. Bariş (1988)
Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases.
U. Prakash (1985)
Mesothelioma and radical multimodality therapy: who benefits?
D. Sugarbaker (1995)
Malignant pleural mesothelioma.
C. Boutin (1998)
Diffuse malignant mesothelioma of pleura: Diagnosis and survival in 92 cases
V. Adams (1986)
New developments in asbestos-induced pleural disease.
D. Schwartz (1991)
P1-140: Outcomes with a platinum plus gemcitabine or pemetrexed as first-line systemic therapy for malignant pleural mesothelioma in British Columbia: a review of province-wide practice
C. Lee (2007)
Environmental fiber-induced pleuro-pulmonary diseases in an Anatolian village: an epidemiologic study.
M. Artvinli (1982)
Pathology of mesothelioma.
J. M. Corson (2004)
Incidence of Malignant Pleural Mesothelioma due to Environmental Asbestos Fiber Exposure in the Southeast of Turkey
A. Şenyiğit (2000)
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
779 Malignant pleural mesothelioma in childhood: A case report
M. Gülhan (1997)
Malignant mesothelioma and erionite exposure.
Z. Selçuk (1999)
Malignant Pleural Mesothelioma Caused by Environmental Exposure to Asbestos in the Southeast of Turkey : CT Findings in 117 Patients
H. Leblebı̇cı̇a (2000)
Malignant mesothelioma of the pleura: Review of 123 patients
J. Brenner (1982)
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
P. Borasio (2008)
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
A. Renshaw (1997)
Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases.
Z. Selçuk (1992)
Pathology of mesothelioma
K. Inai (2008)
Prognose, Staging und Therapie des malignen Pleuramesothelioms
W. Neumeister (2002)
Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.
E. Chailleux (1988)
Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey
ZT Selcuk (1992)
Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort.
M. Metintas (1999)
Lung diseases due to environmental exposures to erionite and asbestos in Turkey.
S. Emri (2002)
[Prognosis, staging and therapy of malignant pleural mesothelioma].
W. Neumeister (2002)
Dabouis G Pioche D de Lajartre M de Lajartre AY Rembeaux A Chailleux E (2012)
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Environmental asbestos exposure and malignant pleural mesothelioma.
M. Metintas (1999)
[Malignant pleural mesothelioma].
Q. Kong (1983)
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
Multimodality management of malignant pleural mesothelioma.
D. Sugarbaker (1998)
Malignant Pleural Mesotheliomas: An Environmental Health Risk in Southeast Turkey
K. Müller (2000)
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma
A. Favaretto (2003)
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging
C. Boutin (1993)
Fibrous zeolite (erionite)-related diseases in Turkey.
Baris Yi (1991)
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
Malignant pleural mesothelioma from nonoccupational asbestos exposure in Metsovo (north-west Greece): slow end of an epidemic?
K. Sakellariou (1996)
Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005
B. Price (2009)
Malignant mesothelioma 1982: review of 4710 published cases.
G. Hillerdal (1983)
Tumors of the Pleura and Mediastinum
M. Sovak (2008)
State of the Art: Pleuroscopy
P. Lee (2007)
Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study
B. Castagneto (2005)
Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: A four‐year study in the cappadocian region of turkey
I. Bariş (1987)
Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics.
M. Metintas (2001)
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
ENVIRONMENTAL MESOTHELIOMA IN TURKEY
Y. Bariş (1979)
Abeloff's Clinical Oncology
J. Niederhuber (2013)
Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.
K. Antman (1988)
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
Malignant mesothelioma of the pleura.
R. J. Pisani (1988)
Trimodality therapy for malignant pleural mesothelioma.
G. Buduhan (2009)
The role of environmental and occupational exposures in Turkish immigrants with fibre-related disease.
P. Dumortier (2001)
Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.
M. Pistolesi (2004)
Mesothelioma and mineral fibers
J. Wagner (1986)
Mesothelioma and mineral fibers. Cancer
JC Wagner (1986)
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis
C. Boutin (1993)
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.
D. Yates (1997)
Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area.
S. Metintaş (2002)
Latency periods in asbestos-related mesothelioma of the pleura.
C. Bianchi (1997)
Malignant Mesothelioma and Occupational Exposure to Asbestos: A Clinicopathological Correlation of 1445 Cases
V. Roggli (2002)
Contemporary management of malignant pleural mesothelioma.
E. Butchart (1999)
B. Robinson (2005)
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
Diagnosis of pleural malignant mesothelioma in life—a practical approach
D. Whitaker (1984)
Asbestos and the pleura: a review.
D. Cugell (2004)
Pleural biopsy in the diagnosis of malignant mesothelioma.
A. Herbert (1982)
Current concepts in malignant pleural mesothelioma
A. Kaufman (2008)
Malignant pleural mesothelioma: current concepts in treatment
A. Tsiouris (2007)
Current concepts in chemotherapy for malignant pleural mesothelioma
J. Sørensen (2008)
Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients.
L. Tammilehto (1992)
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
This paper is referenced by
Risk Factors of Mortality from All Asbestos-Related Diseases: A Competing Risk Analysis
Rafael Abós-Herràndiz (2017)
The Role of Immunohistochemistry Studies in Distinguishing Malignant Mesothelioma from Metastatic Lung Carcinoma in Malignant Pleural Effusion
Monireh Halimi (2019)
Characterization of malignant pleural mesothelioma : possibilities for an individualized therapeutic arsenal
Adam Szulkin (2014)
Clinicopathological features of patients with malignant mesothelioma in a multicenter, case-control study: no role for ABO-Rh blood groups.
G. Utkan (2013)
Chemosensitivity and resistance testing in malignant effusions with focus on primary malignant mesothelioma and metastatic adenocarcinoma
Adam Szulkin (2016)
Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey.
M. Kuçukoner (2014)
The clinicopathological characteristics with long-term outcomes in malignant mesothelioma
M. Dogan (2014)
Epidemiology of Environmental Exposure and Malignant Mesothelioma.
Bian Liu (2017)
Influence of AQP1 on cell adhesion, migration, and tumor sphere formation in malignant pleural mesothelioma is substratum- and histological-type dependent.
Rajesh M. Jagirdar (2016)